183 related articles for article (PubMed ID: 20547759)
1. The repressing function of the oncoprotein BCL-3 requires CtBP, while its polyubiquitination and degradation involve the E3 ligase TBLR1.
Keutgens A; Shostak K; Close P; Zhang X; Hennuy B; Aussems M; Chapelle JP; Viatour P; Gothot A; Fillet M; Chariot A
Mol Cell Biol; 2010 Aug; 30(16):4006-21. PubMed ID: 20547759
[TBL] [Abstract][Full Text] [Related]
2. BCL-3 degradation involves its polyubiquitination through a FBW7-independent pathway and its binding to the proteasome subunit PSMB1.
Keutgens A; Zhang X; Shostak K; Robert I; Olivier S; Vanderplasschen A; Chapelle JP; Viatour P; Merville MP; Bex F; Gothot A; Chariot A
J Biol Chem; 2010 Aug; 285(33):25831-40. PubMed ID: 20558726
[TBL] [Abstract][Full Text] [Related]
3. The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators.
Dechend R; Hirano F; Lehmann K; Heissmeyer V; Ansieau S; Wulczyn FG; Scheidereit C; Leutz A
Oncogene; 1999 Jun; 18(22):3316-23. PubMed ID: 10362352
[TBL] [Abstract][Full Text] [Related]
4. GSK3-mediated BCL-3 phosphorylation modulates its degradation and its oncogenicity.
Viatour P; Dejardin E; Warnier M; Lair F; Claudio E; Bureau F; Marine JC; Merville MP; Maurer U; Green D; Piette J; Siebenlist U; Bours V; Chariot A
Mol Cell; 2004 Oct; 16(1):35-45. PubMed ID: 15469820
[TBL] [Abstract][Full Text] [Related]
5. The bcl-3 proto-oncogene encodes a nuclear I kappa B-like molecule that preferentially interacts with NF-kappa B p50 and p52 in a phosphorylation-dependent manner.
Nolan GP; Fujita T; Bhatia K; Huppi C; Liou HC; Scott ML; Baltimore D
Mol Cell Biol; 1993 Jun; 13(6):3557-66. PubMed ID: 8497270
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of transcription by B cell Leukemia 3 (Bcl-3) protein requires interaction with nuclear factor κB (NF-κB) p50.
Collins PE; Kiely PA; Carmody RJ
J Biol Chem; 2014 Mar; 289(10):7059-7067. PubMed ID: 24459141
[TBL] [Abstract][Full Text] [Related]
7. Mapping the Interaction of B Cell Leukemia 3 (BCL-3) and Nuclear Factor κB (NF-κB) p50 Identifies a BCL-3-mimetic Anti-inflammatory Peptide.
Collins PE; Grassia G; Colleran A; Kiely PA; Ialenti A; Maffia P; Carmody RJ
J Biol Chem; 2015 Jun; 290(25):15687-15696. PubMed ID: 25922067
[TBL] [Abstract][Full Text] [Related]
8. Role of histone H2A ubiquitination in Polycomb silencing.
Wang H; Wang L; Erdjument-Bromage H; Vidal M; Tempst P; Jones RS; Zhang Y
Nature; 2004 Oct; 431(7010):873-8. PubMed ID: 15386022
[TBL] [Abstract][Full Text] [Related]
9. The BCL-6 POZ domain and other POZ domains interact with the co-repressors N-CoR and SMRT.
Huynh KD; Bardwell VJ
Oncogene; 1998 Nov; 17(19):2473-84. PubMed ID: 9824158
[TBL] [Abstract][Full Text] [Related]
10. Shared pathways of IkappaB kinase-induced SCF(betaTrCP)-mediated ubiquitination and degradation for the NF-kappaB precursor p105 and IkappaBalpha.
Heissmeyer V; Krappmann D; Hatada EN; Scheidereit C
Mol Cell Biol; 2001 Feb; 21(4):1024-35. PubMed ID: 11158290
[TBL] [Abstract][Full Text] [Related]
11. Ikaros interactions with CtBP reveal a repression mechanism that is independent of histone deacetylase activity.
Koipally J; Georgopoulos K
J Biol Chem; 2000 Jun; 275(26):19594-602. PubMed ID: 10766745
[TBL] [Abstract][Full Text] [Related]
12. Differential regulation of HIC1 target genes by CtBP and NuRD, via an acetylation/SUMOylation switch, in quiescent versus proliferating cells.
Van Rechem C; Boulay G; Pinte S; Stankovic-Valentin N; Guérardel C; Leprince D
Mol Cell Biol; 2010 Aug; 30(16):4045-59. PubMed ID: 20547755
[TBL] [Abstract][Full Text] [Related]
13. Association of COOH-terminal-binding protein (CtBP) and MEF2-interacting transcription repressor (MITR) contributes to transcriptional repression of the MEF2 transcription factor.
Zhang CL; McKinsey TA; Lu JR; Olson EN
J Biol Chem; 2001 Jan; 276(1):35-9. PubMed ID: 11022042
[TBL] [Abstract][Full Text] [Related]
14. Signal-dependent degradation of IkappaBalpha is mediated by an inducible destruction box that can be transferred to NF-kappaB, bcl-3 or p53.
Wulczyn FG; Krappmann D; Scheidereit C
Nucleic Acids Res; 1998 Apr; 26(7):1724-30. PubMed ID: 9512545
[TBL] [Abstract][Full Text] [Related]
15. CD40 regulates the processing of NF-kappaB2 p100 to p52.
Coope HJ; Atkinson PG; Huhse B; Belich M; Janzen J; Holman MJ; Klaus GG; Johnston LH; Ley SC
EMBO J; 2002 Oct; 21(20):5375-85. PubMed ID: 12374738
[TBL] [Abstract][Full Text] [Related]
16. A novel corepressor, BCoR-L1, represses transcription through an interaction with CtBP.
Pagan JK; Arnold J; Hanchard KJ; Kumar R; Bruno T; Jones MJ; Richard DJ; Forrest A; Spurdle A; Verdin E; Crossley M; Fanciulli M; Chenevix-Trench G; Young DB; Khanna KK
J Biol Chem; 2007 May; 282(20):15248-57. PubMed ID: 17379597
[TBL] [Abstract][Full Text] [Related]
17. Hepatoma-derived growth factor represses SET and MYND domain containing 1 gene expression through interaction with C-terminal binding protein.
Yang J; Everett AD
J Mol Biol; 2009 Mar; 386(4):938-50. PubMed ID: 19162039
[TBL] [Abstract][Full Text] [Related]
18. NF-kappaB p105 is a target of IkappaB kinases and controls signal induction of Bcl-3-p50 complexes.
Heissmeyer V; Krappmann D; Wulczyn FG; Scheidereit C
EMBO J; 1999 Sep; 18(17):4766-78. PubMed ID: 10469655
[TBL] [Abstract][Full Text] [Related]
19. Id1 enhances RING1b E3 ubiquitin ligase activity through the Mel-18/Bmi-1 polycomb group complex.
Qian T; Lee JY; Park JH; Kim HJ; Kong G
Oncogene; 2010 Oct; 29(43):5818-27. PubMed ID: 20697353
[TBL] [Abstract][Full Text] [Related]
20. Multiple activities contribute to Pc2 E3 function.
Kagey MH; Melhuish TA; Powers SE; Wotton D
EMBO J; 2005 Jan; 24(1):108-19. PubMed ID: 15592428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
